A Dose Escalation Study of MK1775 in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005)
Status:
Terminated
Trial end date:
2011-06-15
Target enrollment:
Participant gender:
Summary
The study evaluates safety of MK-1775 in monotherapy, and in combination with 5-Fluorouracil
(5-FU) alone or with 5-FU/cis-diamminedichloroplatinum (CDDP) in Japanese participants with
solid tumor. The primary hypothesis is that MK-1775 is safe and tolerable in participants
with locally advanced or metastatic solid tumors.